Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas - BMC Cancer
- ️Arja-Jukkola-Vuorinen
- ️Tue Jun 21 2011
Table 3 Number of positive immunostaining results in different subgroups and corresponding p-values.
Triple-negative | ER+/PR+/HER2- | p-value | Basal-like | Non-basal-like | p-value | |
|---|---|---|---|---|---|---|
Cytoplasmic PRDX III | 3 (8.1%) | 9 (21.4%) | 0.10 | 2 (6.5%) | 1 (16.7%) | 0.42 |
Nuclear PRDX III | 3 (8.1%) | 10 (23.8%) | 0.060 | 3 (9.7%) | 0 (0.0%) | 0.43 |
Cytoplasmic PRDX IV | 27 (73.0%) | 20 (47.6%) | 0.022 | 22 (71.0%) | 5 (83.3%) | 0.53 |
8-OHdG | 13 (37.1%) | 30 (73.2%) | 0.0016 | 10 (33.3%) | 3 (60.0%) | 0.25 |
Nrf2 | 12 (33.3%) | 11 (26.8%) | 0.53 | 10 (33.3%) | 2 (33.3%) | 1.0 |
Keap1 | 26 (76.5%) | 16 (39.0%) | 0.0011 | 22 (78.6%) | 4 (66.7%) | 0.53 |
- Criteria for positive immunostaining for each antibody are described in the Materials and Methods section.